methyl N-[(4-chlorophenyl)sulfonyl]-4-nitrobenzenesulfinimidoate

CCG-4986 is an RGS protein inhibitor. CCG-4986 inhibits protein activity by covalently modifying the Cys-132 site of RGS4. CCG-4986 can be used to study diseases related to dysregulated G protein-coupled receptor (GPCR) signaling, such as Parkinson's disease and opioid addiction[1].

RGS4

[1] Kimple AJ, et al. The RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction face. Biochim Biophys Acta. 2007 Sep;1774(9):1213-20. DOI:10.1016/j.bbapap.2007.06.002